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Abstract 
Bladder tumours in early-onset patients are rare and seem to exhibit unique clinicopathological 
features. Only few studies have investigated somatic alterations in this specific age of onset group 
and evidence is accumulating of a distinct molecular behaviour of early-onset bladder tumours. We 
collected the largest cohort of early-onset tumours of patients 45 years old or younger and aimed 
to test genomic alterations typically found in bladder cancer. Tumours of 118 early-onset patients 
were compared with a consecutive group of 113 cases. Immunohistochemistry of TP53, CK20 and 
Ki-67 was carried out. Molecular analysis was conducted to test for loss of heterozygosity of 
chromosome 9 and 17, as well as TP53 and FGFR3 mutations. Fisher´s exact and chi-squared test 
were appropriately used. No differences in grade/stage characteristics were observed. 
Overexpressed TP53 was differentially distributed between the two groups. TP53 nuclear 
accumulation was significantly more frequent in early-onset papillomas, PUNLMPs and pTa 
low-grade tumours compared to the consecutive cohort (p=0.005). Moreover, chromosome 9 
deletions (29.5% vs. 44.6%) and FGFR3 mutations (34.5% vs. 63.7%) were less often detected in 
early-onset patients (p=0.05 and p<0.0001). By comparing the largest cohort of early-onset 
bladder cancer patients with an unselected group, we demonstrated that the typical molecular 
features are not independent of age at diagnosis. Our study supports the hypothesis of a distinct 
biological behaviour in early-onset tumours. 
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Introduction 
Urothelial bladder cancer (UBC) usually occurs 
late in life, with a mean age at diagnosis of 
approximately 67 years [1]. UBC is a heterogeneous 
disease, both clinically and molecularly. Low-grade 
non-muscle invasive tumours are associated with 
activating mutations of FGFR3 and PIK3CA and a 
lower risk of progression, whereas TP53 and RB 
pathway alterations play a key role in the 
development of high-grade non- and muscle-invasive 
UBC [2-5]. Additionally, total or partial loss of 
chromosome 9 is found in almost half of the tumours 
of all stages and grades [6, 7]. 
Worldwide estimates of cancer incidences for 
2012 indicate that the proportion of UBC in patients 
younger than 45 years is at about 3.4% [8]. Because of 
these low incidence rates and since no uniform 
threshold is used for young patients, the natural 
history is still under debate. However evidence is 
accumulating, that especially tumours of patients of 
the first two decades of life are more frequently 
low-grade/-stage with a favourable prognosis [9]. 
Besides distinct clinicopathological features, very few 
studies of paediatric and adolescent patients reported, 
that molecular alterations in paediatric and adolescent 
patients were much rarer compared to typical UBC 
samples [10-14]. These unexpected results gave 
evidence, that tumours of this age of onset group may 
represent a distinct biological entity. However, only 
small sample-sized studies were reported and thus 
these findings have still to be validated. 
The aim of our study was to investigate specific 
molecular alterations of UBC in the largest cohort to 
date of early-onset patients, defined herein for the 
study as patients aged 45 or younger. 
Immunohistochemical analysis was performed to 
detect CK20, Ki-67 and TP53 expression levels. In 
addition, we investigated the frequencies of loss of 
heterozygosity (LOH) of chromosome 9 and 17. 
Moreover, molecular analysis revealed mutations in 
the FGFR3 and TP53 gene. All obtained results were 
compared with a consecutive, unselected cohort of 
patients.  
Materials and methods 
Tumour samples  
118 patients aged 45 or younger were identified 
from 1991 until 2001 from the files of the contributing 
Institutes of Pathology. 113 consecutive cases were 
included from the period between 1996 and 2002. For 
each case, formalin-fixed paraffin-embedded primary 
UBC and normal tissues were available and 
reclassified according to the 2016 WHO classification 
by two experienced uropathologists (A.H., J.G.) [15]. 
Figure 1 demonstrates representative images of the 
histopathological specimens of early-onset patients. 
Eight urothelial papillomas and ten samples of 
papillary urothelial neoplasia of low malignant 
potential (PUNLMP) were included. Due to similar 
molecular features reported, they were grouped 
together with pTa low-grade tumours [16]. Table 1 
shows the characteristics of the two cohorts. 
Institutional Review Board approval (University 
Hospital Erlangen) was obtained for molecular 
analysis on archival material.  
 
Table 1. Clinicopathological characteristics of the two different 
cohorts.  
Characteristics Early-onset 
group 
Consecutive 
group 
Group 
comparison 
(n=118) (n=113) p-value 
Age distribution, yr    
    Minimum/maximum 17/45 48/87  
    Mean ± SD 37.6 ± 6.5 69.8 ± 8.4  
    Median age 39 70  
Age categories, yr    
    ≤ 20 3 -  
    21-25 4 -  
    26-30 8 -  
    31-35 23 -  
    36-40 32 -  
    41-45 48 -  
    >45 - 113  
Gender, No.       
    Male  92 (79.3) 89 (78.8) p=1.0 
    Female  24 (20.7) 24 (21.2)  
    Not available  2   0    
Stage/grade distribution I, No.      
    Urothelial papilloma 7  0   
    Inverted urothelial papilloma 0  1   
    PUNLMP 0  10   
    pTa low-grade 56  62   
    pTa high-grade 20  9   
    pT1 low-grade 4  1   
    pT1 high-grade 12  23   
    pT2 high-grade 8  7   
    pT3 high-grade 8  0   
    pT4 high-grade 1  0   
    Not available  2  0   
Stage/grade distribution II, No.      
    Inverted/ Urothelial papilloma &  
    PUNLMP & pTa low-grade  
63 (54.3) 73 (64.6) p=0.08 
    pTa high-grade & pT1 36 (31.0) 33 (29.2)  
    ≥ pT2 17 (14.7) 7 (6.2)  
    Not available  2  0   
SD, standard deviation; PUNLMP, papillary urothelial neoplasm of low malignant 
potential. 
 
 
Immunohistochemistry (IHC) 
IHC of TP53, CK20 and Ki-67 were performed 
using whole tumour sections and an avidin-biotin 
peroxidase method with a 3,3’-diaminobenzidine 
chromatogen. According to the manufacturer’s 
instructions, IHC was carried out in a NEXES 
immunostainer (Ventana, Tucson, AZ, USA). 
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Anti-TP53 (mouse monoclonal IgG, clone Bp53-12 
(sc-263) [Santa Cruz Biotechnology, Inc, Santa Cruz, 
CA, USA], dilution 1:1000), anti-CK20 (mouse 
monoclonal IgG2a, clone IT-Ks20.8 (61026) [Progen 
Biotechnik GmbH, Heidelberg, Germany]; dilution 
1:10) and anti-Ki-67 (mouse monoclonal IgG1, clone 
MIB1 (M7240) [Dako, Glostrup, Denmark], dilution 
1:50) were used as primary antibodies. The slides 
were evaluated by one surgical pathologist (A.H.). 
Nuclear staining reaction for TP53 was scored from 
0% to 100% in 10% increments. The intensity of the 
TP53 staining was recorded as negative, weak or 
strong. Considering a cut-off level at 10% of positive 
cells, three different categories were defined: ≤10% 
negative, >10% weak or >10% strong. 
Anti-Ki-67-immunostaining was scored from 0% to 
5% in 1% increments and from 5% to 100% in 5% 
increments and cut-off level for increased 
proliferation was defined at 10%. Staining of CK20 as 
a urothelial associated marker was defined as either 
normal (cytoplasmic staining pattern of the superficial 
cells only) or aberrant (negative or more than 10% of 
the urothelial cells stained) according to Harnden et 
al. [17].  
 
 
Figure 1: Representative images of histopathological specimens of the early-onset tumours (magnification: x100) A, papilloma, no analysed mutation or deletion was 
identified. B, pTa low-grade tumour, a FGFR3 mutation (p.S249C) was detected. C, pTa low-grade tumour, none of the analysed alterations was observed. D, pTa 
high-grade tumour, a mutation of the FGFR3 mutation (p.S249C) and LOH of chromosome 9 were observed. E, pT1 high-grade tumour, not mutated. F, pT2 
high-grade tumour, a TP53 mutation in exon 5 was identified. 
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Microdissection and DNA isolation 
Tumour and normal DNA was isolated as 
described previously [18]. An experienced pathologist 
(A.H.) marked areas with highest tumour cell density 
on a representative H&E-stained section. 5-μm tissue 
sections were deparaffinised and tumour and 
non-malignant tissue were separately microdissected 
in sterile tubes by using sterile needles. Due to 
separation, tumour cells with a purity of at least 80% 
were obtained. DNA isolation was performed using 
the High Pure PCR Template Preparation Kit (Roche 
Diagnostics, Mannheim, Germany) according to the 
manufacturer’s instructions. 
Detection of LOH 
For detection of LOH two microsatellite markers 
at chromosomal region 9p21 (D9S304, D9S1751), two 
markers at 9q (D9S303, D9S747) and one marker at 
17p13.1 (p53Alu) were used as described previously 
[19]. The Polymerase chain reaction (PCR) 
amplification was performed in a MJ Research 
Thermocycler (PTC100, MJ Research, Watertown, 
MA, USA). By using 6.7% polyacrylamide/50% urea 
gel electrophoresis (1h, 1500V, 55°C) PCR products 
were analysed in a SequiGen sequencing gel chamber 
(BioRad, Hercules, CA, USA) followed by silver 
nitrate staining [20]. In informative cases LOH was 
defined as a decrease in signal intensity of the tumour 
sample allele to at least 50% relative to the matched 
normal DNA allele. All cases of LOH were confirmed 
at least once. Silver nitrate gels were evaluated 
independently by three different investigators (J.G., 
R.Sch., R.S.).  
FGFR3 and TP53 mutation analysis 
SNaPshot method was used to analyse FGFR3 
mutations, as described previously [21]. Three regions 
of the FGFR3 gene comprising the mutations were 
amplified simultaneously in a multiplex PCR reaction. 
Eight SNaPshot primers were used to detect nine 
mutations. An automatic sequencer (ABI Prism 310) 
analysed the extended primers. Direct sequencing of 
exons 5-9 of the TP53 gene was assessed as described 
previously [22]. Identified mutations were verified in 
a second sequencing run to rule out polymerase 
errors. 
Statistical analysis 
Two-sided Fisher´s exact and chi-squared test 
were appropriately used to assess differences in the 
distributions of tested markers between both groups. 
P-values less than 0.05 were interpreted as statistically 
significant. All analyses were performed using R 
version 3.2.5 (www.r-project.org). 
Results 
Immunohistochemical analysis of CK20, Ki-67 
and TP53  
Table 2 summarizes the results of the IHC of 
CK20, Ki-67 and TP53. Neither the staining pattern of 
Ki-67, nor the expression of the differentiation marker 
CK20 showed a significant difference between the two 
groups. When we differentiated the aberrant staining 
of CK20 in negative or >10% of stained cells, we 
observed a significantly higher number of negative 
staining among the early-onset compared to the 
consecutive cases (p=0.03).  
 
Table 2. Expression of CK20, Ki-67 and TP53 in the two different 
groups.  
 Early-onset 
group 
Consecutive 
group 
Group 
comparison 
IHC marker n (%) n (%) p-value 
Ki-67 IHC      
    ≤10% 63 (58.9) 55 (49.1) p=0.19 
    >10% 44 (41.1) 57 (50.9)  
    Not available 11   1    
CK20 IHC      
    Normal 37 (37.4) 40 (35.4) p=0.88 
    Aberrant 62 (62.6) 73 (64.6)  
          Negative 13 (13.1) 5 (4.4)  
          >10% of stained cells 49 (49.5) 68 (60.2)  
    Not available  19   0    
TP53 IHC I      
    ≤10% negative & >10% weak 82 (73.9) 90 (79.6) p=0.39 
    >10% strong 29 (26.1) 23 (20.4)  
    Not available  7  0   
TP53 IHC according to grade/stage      
Inverted/Urothelial papilloma & 
PUNLMP & pTa low-grade 
     
        ≤10% negative & >10% weak 48 (77.4) 69 (94.5) p=0.005 
        >10% strong 14 (22.6) 4 (5.5)  
        Not available  1  0   
    pTa high-grade & pT1      
        ≤10% negative & >10% weak 27 (79.4) 20 (60.6) p=0.16 
        >10% strong 7 (20.6) 13 (39.4)  
        Not available  2  0   
    ≥ pT2      
        ≤10% negative & >10% weak 7 (50.0) 1 (14.3) p=0.17 
        >10% strong 7 (50.0) 6 (85.7)  
        Not available  3  0   
TP53 IHC III      
    ≤10% negative 45 (40.6) 81 (71.7) p<0.0001 
    >10% weak 37 (33.3) 9 (8.0)  
    >10% strong 29  (26.1) 23 (20.3)  
    Not available 7  0   
IHC, immunohistochemistry; PUNLMP, papillary urothelial neoplasm of low 
malignant potential. 
 
 
IHC of TP53 was performed in 111 early-onset 
and all consecutive patients. The intensity was 
recorded as negative in 112, weak in 52 and strong in 
60 cases. Similar percentages of positive cells were 
obtained in the different cohorts (data not shown). A 
>10% strong staining of TP53 was observed in 29 of 
the early-onset cases and was not significantly 
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different to the 23 stained consecutive samples 
(p=0.39). When we distinguished the tumours 
according to grade/stage, we detected 14 (22.6%) out 
of 62 early-onset papillomas, PUNLMPs and pTa 
low-grade tumours with >10% strong staining. In 
contrast, only 4 (5.5%) out of 73 consecutive samples 
of the same grade/stage characteristics were stained 
(p=0.005). Remarkably, when we also considered a 
>10% weak staining, 66 (59.4%) early-onset cases 
showed a >10% weak or strong nuclear accumulation 
of TP53, whereas only 32 (28.3%) consecutive tumours 
presenting both intensity categories were included 
(p<0.0001).  
 
 
 
LOH of chromosome 17 and mutations of the 
TP53 gene 
The analysis of LOH of chromosome 17 and the 
TP53 gene did not reveal any significant difference 
between the early-onset and unselected group (Table 
3). All five TP53 mutations of the early-onset cases 
were transitions (G:CA:T; A:TG:C) and all but 
one (silent mutation) were miss-sense mutations in 
the exons 8, 6 and 5. Two mutation carriers were >10% 
strongly stained for TP53 (Figure 2). Furthermore, ten 
mutations were discovered in seven (6.2%) 
consecutive patients showing a >10% strong IHC. 
Nine transitions (G:CA:T; C:TT:A) and one 
transversion (G:AC:T) were identified. Seven muta-
tions in exon 8 led to a change in the corresponding 
amino-acid. One non-sense and two miss-sense 
mutations were detected in exons 6, 7 and 9.  
 
 
Figure 2: Representative examples of early-onset tumours for TP53 immunohistochemical staining. A, pTa low-grade tumour with a weak expression of TP53 and 
no TP53 mutation (x400). B, pTa low-grade tumour with strong expression of TP53 and not mutated (x400). C, Strong expression of TP53 and a mutation in exon 
8 were identified in pT2 high-grade tumour (x400). Representative example of sequence analysis of the shown mutated early-onset tumour. The mutation p.C275Y 
(TGT  TAT) was detected by using Sanger sequencing. 
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Table 3. Molecular changes of the studied cohorts.  
 Early-onset 
group 
Consecutive 
group 
Group 
comparison 
 n (%) n (%) p-value 
LOH of chromosome 17      
    No 63 (92.6) 62 (91.2) p=1.0 
    Yes 5 (7.4) 6 (8.8)  
    Not informative 28  42   
    Not available 22   3    
TP53 gene      
    Wild-type 100 (95.2) 106 (93.8) p=0.87 
    Mutated 5 (4.8) 7 (6.2)  
    Not available  13  0   
LOH of chromosome 9      
    No 67 (70.5) 46 (55.4) p=0.053 
    Yes 28 (29.5) 37 (44.6)  
          9p 6 (6.3) 4 (4.8)  
          9q 13 (13.7) 24 (28.9)  
          9p+q 9 (9.5) 9 (10.9)  
    Not informative 9  30   
    Not available 14   0    
FGFR3 gene       
    Wild-type  74 (65.5) 41 (36.3) p<0.0001 
    Mutation  39 (34.5) 72 (63.7)  
          p.S249C 24 (21.3) 40 (35.4)  
          p.Y375C 11 (9.7) 15 (13.3)  
          Other mutations 4 (3.5) 17 (15.0)  
    Not available 5   0    
LOH; Loss of heterozygosity; 
 
 
LOH of chromosome 9 and FGFR3 mutation 
analysis  
A borderline significantly lower percentage of 
deletions of chromosome 9 was found among the 
early-onset (29.5%) compared to the consecutive 
series (44.6%) (p=0.053, Table 3). Moreover, the 
distribution of chromosome 9 alterations (9p+q vs 9p 
vs 9q) was not different between the two cohorts 
(p=0.31). FGFR3 analysis revealed mutations in 39 
(34.5%) of the 113 analysed early-onset tumours 
(Table 3). Among the unselected cohort, a 
significantly higher number of 72 (63.7%) patients 
were detected as mutated (p<0.0001). In both cohorts 
we identified p.S249C and p.Y375C mutations as the 
most frequent ones and no difference of the 
distribution was observed (p=0.24). The frequency of 
FGFR3 mutations in different age categories of 
early-onset patients are shown in Supplementary 
table 1. Due to low numbers of patients <30 years, we 
used the median age of 39 to stratify the early-onset 
cohort. A significantly lower frequency of 12 (23.5%) 
out of 51 patients aged <39 were mutated compared to 
27 (43.5%) out of 62 early-onset patients ≥39 (p=0.04). 
In contrast, by using the median of 70 years for the 
consecutive cohort no difference of the distribution 
was observed (p=0.39, data not shown). 
Summarized, any of the typical alterations of 
UBC were detected in 88 (77.9%) out of 113 analysed 
consecutive cases, whereas only half of the early-onset 
tumours were identified as mutated (p<0.0001, 
Supplementary figure 1). Mutations in FGFR3 and 
TP53 were mutually exclusive, only one consecutive 
patient presented with a simultaneous mutation.  
 
Discussion 
Only few studies have attempted to investigate 
the biological behaviour of early-onset tumours, with 
no clear definition regarding the maximum age of 
onset [9]. Some studies showed a better clinical 
outcome, especially for patients of the first two 
decades presenting low-grade and -stage tumours [9, 
14, 23]. In contrast, other studies did not observe any 
difference at the clinicopathological level in the 
various groups of onset [24]. In other tumour entities 
the threshold between early-onset and consecutive 
cancer is mostly defined in the middle years. 
Early-onset colorectal cancer is mainly reported for 
patients younger than 50, with the average age of 
diagnosis of about 70 years [25, 26]. Compared to 
elderly colorectal cancer, some risk factors and 
molecular features differ in young patients [27]. As 
the peak of UBC presents in the seventh decade of life 
and due to low incidence rates below age 35, we 
included patients 45 years old or younger. In our 
study, the early-onset and the unselected group did 
not show any difference in the grade/stage 
distribution. The molecular features of young UBC 
are explored even less (summarized in Table 4). 
In elderly patients, mutations of TP53 occur 
commonly in muscle invasive tumours and display a 
key feature in the evolution of carcinoma in situ to an 
invasive disease [28]. In this study, we did not observe 
a difference of TP53 nuclear accumulation among the 
two cohorts using a >10% strong nuclear staining 
pattern as cut-off. Interestingly, when we compared 
these strong positive samples in correlation to 
grade/stage, we detected a distinct distribution 
among the two series. A significantly higher number 
of TP53 strongly positive papillomas, PUNLMPS and 
pTa low-grade tumours were found in the early-onset 
group. Our results confirmed a previous study by 
Linn et al. describing 73 patients aged 30 years old or 
younger, where 67% of early-onset tumours showed a 
high expression of TP53 by using immunohisto-
chemistry [13]. In contrast to our study the intensity of 
the TP53 staining was not considered. Since almost all 
tumour samples were non-muscle invasive, the 
finding of a frequent TP53 overexpression was an 
unexpected result. When we also included a >10% 
weak together with a strong IHC staining, we 
detected as well a significantly higher frequency of 
positive cells among the early-onset cases.  
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Table 4. Summary of the different molecular studies of early-onset patients. 
Author Weyerer 
2017 
Huang 
2015 
Williamson 
2014 
Wild 
2007 
Migaldi 
2004 
Linn 
1998 
n (%) n (%) n (%) n (%) n (%) n (%) 
Number of early-onset patients  118 45 17 14 50 73 
Age, range (yr) 17-45 ≤30 6-26 4-19 <45 <30 
Abnormal expression of CK20a 62/99 (62.6) - - 2/13 (15.4) - - 
High expression of Mib1/Ki-67 44/107 (41.1)b - - 2/13 (15.4)b 22/50 (44)c - 
TP53 positive staining 29/111 (26.1)d - - 1/13 (7.7)b 28/50 (56)e 49/73 (67)b 
TP53 mutation 5/105 (4.8)f  - 0/17g 2/12 (16.7)f - - 
Deletion of chromosome 17 5/68 (7.4)h - 1/17 (5.9)i Gain 0/4h  - 15/72 (20.8)i 
Deletion of chromosome 9 28/95 (29.5)j - 3/17 (17.7)k 0/6j - 9/67 (13.4)k 
FGFR3 mutation 39/113 (34.5)l 13/39 (33.3)m 0/17n 0/10l - - 
a In both studies 10% of stained cells were used as cut-off. 
b Cut-off level was defined at 10%. 
c Cut-off level was defined at 15%. 
d Cut-off level was defined at 10% and the intensity was considered. 
e Cut-off level was defined at 20%. 
f Exons 5 to 9 were analysed. 
g Exons 5, 7 and 8 were analysed. 
h Marker at chromosome 17p.13.1 (p53Alu) was used. 
i Chromosome enumeration probe/ centromeric probe for chromosome 17 was used. 
j Two microsatellite markers at chromosomal region 9p21 (D9S304, D9S1751) and two markers at chromosome arm 9q (D9S303, D9S747) were used. 
k Locus specific indicator probe for 9p21/ centromeric probe was used.  
l Nine common mutations were tested by SNaPshot method. 
m Immunohistochemistry was used for detection. 
n Exons 7, 10 and 15 were analysed. 
 
 
By performing molecular analysis of TP53 we 
identified a similar percentage of mutations in both 
cohorts. As it has been shown that a strong staining 
correlates with TP53 mutations [29], we did not 
identify a >10% weak sample as mutated. In a study 
of atypical bronchial epithelium the lack of TP53 
mutation accompanied with high expressed TP53 
without considering the intensity was reported [30]. 
Due to the absence of mutations the authors 
suggested that the stained TP53 might be wild-type 
and might act as a protector against premalignant 
lesions. Considering both intensity categories and the 
very frequent staining in both early-onset studies, it 
appears that wild-type TP53 was identified and that 
young samples might also try to activate molecular 
protection mechanisms. Of course there might also be 
other mechanisms through which the TP53 staining 
may occur among young cases. For example, the 
accumulation might as well be due to an inactivation 
of degeneration pathways [31]. In summary, our 
results support the hypothesis that TP53 positivity 
and the distribution according to grade/stage 
subphenotypes may be dependent from age of disease 
onset.  
Deletions of chromosome 9 are frequent 
numerical abnormalities in UBC, do not depend on 
grade/stage distribution and are recognized as one of 
the initial steps in UBC [6, 7]. LOH of chromosome 9 
was only found in 29.5% of early-onset UBC, whereas 
tumours of the consecutive series showed numerical 
abnormalities with a frequency of 44.6%. This finding 
is in line with the two studies of Wild et al. and 
Williamson et al. in which the authors found 
infrequent alterations of chromosome 9 [10, 11]. These 
similar results suggest that early-onset UBC may be 
more genomically stable.  
Activating mutations of FGFR3 are associated 
with low-grade non-muscle invasive UBC, with 
approximately 70% of these tumours carrying 
alterations [4]. In two recently published studies of 
urothelial neoplasms in patients <26 years, the total 
lack of FGFR3 mutations was reported [10, 11], 
although almost all tumours presented with a 
low-grade/stage. An interesting observation in our 
analysis is that within the early-onset series patients 
<39 were significantly and infrequently mutated. 
Therefore, it seems that the difference between early- 
and the regular-onset of the disease is most 
pronounced for very young patients. Huang et al. 
have used IHC of FGFR3 and have reported a 
frequency of 33.3% of positive stained cells among 45 
patients ≤30. Due to clinical differences and since only 
13.3% of patients aged 25 or younger were positively 
stained, they suggested that 25 may represent the 
cut-off level between early- and regular-onset UBC 
[12]. Compared to our study, a much lower sample 
size of early-onset cases was used and the FGFR3 
status was not evaluated by molecular analysis. The 
authors did not compare the clinical behaviour and 
staining pattern with consecutive patients, thus they 
might miss part of the early-onset cases. Summarized, 
we do not think that 25 may indicate the cut-off for 
early-onset UBC. The low frequency of FGFR3 
mutations in young cases adds to the evidence, that 
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mutation profiles and the pathways of carcinogenesis 
of elderly patients may be less important and distinct 
molecular features may be involved in the 
development of early-onset UBC. 
Taken together, in only half of the analysed 
early-onset tumours a typical molecular alteration of 
bladder cancer could be detected. In two recent 
studies of BC in young patients below the age of 20 a 
specific HRAS mutation associated with Costello 
syndrome was found as well as methylation of the 
PCDH7 gene in these and older BC patients, 
suggesting that this may represent a very early 
change [32-34]. In addition, it was recently shown that 
activating mutations in the core promoter of the TERT 
gene were detected more infrequently in early-onset 
compared to consecutive cases [35]. Thus, these 
results add to a different mechanism and more 
investigations in early-onset patients are needed to 
reveal the distinct molecular profile and to better 
characterize these specific patients.  
In conclusion, we demonstrated in the largest 
cohort of early-onset cases studied, that the known 
molecular characteristics of UBC are differentially 
represented in this specific group. In comparison to 
patients younger or older than 45 years, we observed 
an infrequent number of FGFR3 mutations and 
chromosome 9 deletions and a distinct distribution of 
TP53 positivity according to grade/stage among 
young cases. Our data support the hypothesis that the 
typical profile of UBC is not independent of the age of 
disease onset and suggest that early-onset tumours 
represent a differentially biologically driven entity.  
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